Toshimitsu Uenaka, Ph.D.

Toshimitsu Uenaka, Ph.D., serves as the President of Eisai Inc.’s Epochal Precision Anti-Cancer Therapeutics (EPAT), a biologics research site located in Exton, Pennsylvania. He is also Co-Head of Cell Linage and Differentiation (CLD) domain in the Deep Human Biology Learning (DHBL) organization at Eisai. Dr. Uenaka began his Eisai career in 1993 as a biology scientist. Over the subsequent 25-year period, he has served on the frontline of Eisai’s exploratory research of anticancer agents. In 2009, he was promoted to Head of Global Discovery of Oncology Product Creation Unit to lead anticancer agent exploratory research. In 2011, he was named Head of Global Biology, in which he led projects at Eisai Research Institute Andover in Massachusetts. Starting in 2013, he moved to Morphotek’s biologics at Morphotek Inc., a subsidiary of Eisai’s located at Exton, Pennsylvania, where he focused on combining Eisai’s small molecule/naturally derived drug discovery. In November 2015, he discovered MORAb-202, Eisai’s first Antibody-drug Conjugate (ADC). Dr. Uenaka has been in his current role as EPAT President since February, 2019. He later became Co-Head of Cell Linage and Differentiation domain of DHBL in October, 2022 Dr. Uenaka received his Ph.D. from the Graduate School of Pharmaceutical Sciences of the University of Tokyo. He graduated from the Faculty of Pharmaceutical Sciences at the University of Tokyo in 1988, where he later earned his Master’s Degree.